SAN DIEGO, Oct. 28, 2020 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM), an international healthcare solutions company targeting oncological and COVID-19 research, announced today that it has issued a letter to its shareholders providing commentary on the Company’s recent announcements and upcoming plans.
Highlights of the letter include:
| The Company’s rapid pivot and response to COVID-19, including: | ||
| Developing World’s First Rapid Diagnostic Test for Detecting Neutralizing Antibodies | ||
| NeuCovix-HT™: A high throughput, patent-pending diagnostic test that measures levels of functional antibodies in plasma or serum that neutralize the SARS-CoV-2 (COVID-19) virus | ||
| World’s First Face Mask Designed to Capture COVID-19 Virus | ||
| Virus Binding Protein (VBP) | ||
| The Company’s recent oncology-focused research updates, including: | ||
| New Patent re: SBI-183 | ||
| Conversion of Provisionals re: SBI-183 Analogs | ||
| A recently awarded $395,880 phase I Small Business Innovation Research (SBIR) grant by the National Cancer Institute (NCI) to continue research and development of novel small molecules that inhibit the enzymatic activity of QSOX1 based on SBI-183. This success has allowed AXIM to bring on additional staff that are dedicated to the research and development of these analogs. | ||
| The Shareholder Letter details some of the Company’s anticipated key milestone achievements for the end of 2020 and beginning of 2021. | ||
The Company’s Chief Executive Officer John W. Huemoeller II commented: “2020 has been an unexpected and unprecedented year for every industry. I am so proud and humbled by the ability of AXIM’s scientists to swiftly adapt their skills into COVID-19 research and development at the onset of the pandemic. Together, we have brought several much-needed, first-of-its-kind rapid tests to fruition and have done so in a fiscally responsible way that maximizes our budget. In 2021, we look forward to further partnerships and developments as we work to bring our COVID-19 projects to market and continue our oncology-focused research.”
To read the Letter to Shareholders in full, please visit: https://aximbiotech.com/investors/.
About AXIM® Biotechnologies
Founded in 2014, AXIM® Biotechnologies, Inc. (AXIM) is a vertically integrated research and development company focused on changing diagnosis and treatment for oncology and SARS-CoV-2 (COVID-19). AXIM’s COVID-19 rapid neutralizing antibody test is the first rapid diagnostic test measuring levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells. The Company has also begun development of the first-ever face masks that capture and deactivate SARS-CoV-2, enhancing protection of both the user and those surrounding the user. Additionally, the Company is developing rapid diagnostic tests for the early detection of cancer and proprietary small molecules drugs to treat cancer and block metastasis. For more information, please visit www.AXIMBiotech.com.
